LumaCyte’s Analytical Method Recognized in Newly Issued ISO Global Standard for Viral Vector Quantification
LumaCyte has announced a significant milestone for its proprietary analytical technology, revealing that its approach has been formally incorporated into the newly published global standard for gene delivery systems developed by the International Organization for Standardization (ISO). The standard, titled ISO 16921-2:2026: Biotechnology — Gene delivery systems — Part 2: Quantification methods for viral vectors, represents a major step forward in harmonizing analytical methods used in the rapidly evolving fields of cell and gene therapy as well as vaccine development.
This inclusion underscores the growing importance of advanced, standardized analytical technologies in ensuring the quality, safety, and consistency of viral vector-based therapeutics. At the core of LumaCyte’s contribution is its Radiance® platform, which leverages optical and fluidic force-based measurement techniques—an innovative analytical principle now recognized within the ISO framework as a valuable method for viral vector characterization.
Advancing Standardization in Viral Vector Quantification
The publication of ISO 16921-2:2026 comes at a critical juncture for the biotechnology and biopharmaceutical industries. As gene therapies transition from experimental and early clinical stages into large-scale commercial manufacturing, the need for robust, reproducible, and standardized analytical methods has become increasingly urgent.
Viral vectors—such as those used to deliver therapeutic genes into target cells—are fundamental to the success of gene therapies and certain vaccines. Accurate quantification of these vectors, commonly referred to as viral titers, is essential for determining appropriate dosing, maintaining safety margins, and ensuring consistency across manufacturing batches.
However, achieving precise and reliable viral titer measurements has historically been a significant challenge. Variability in measurement techniques, particularly when comparing physical assays (which measure total viral particles) to functional assays (which measure infectious or active particles), has led to discrepancies that can complicate product development and regulatory approval processes.
The ISO 16921-2 standard directly addresses these challenges by establishing comprehensive guidance on quantification methods, including best practices for method selection, measurement protocols, data analysis, and reporting. By providing a globally recognized framework, the standard aims to reduce variability and improve comparability across laboratories, manufacturing sites, and regulatory jurisdictions.
Recognition of LumaCyte’s Radiance® Technology
A key highlight of the new standard is the inclusion of optical and fluidic force-based measurement techniques, the analytical foundation of LumaCyte’s Radiance® platform. This approach represents a novel and highly sensitive method for characterizing viral vectors at the single-particle level.
Unlike traditional methods, which may rely on indirect measurements or bulk analysis, the Radiance® platform enables direct, real-time assessment of viral particles based on their physical and functional properties. By combining optical detection with fluidic forces, the system can distinguish between different particle types and provide detailed insights into viral vector composition and behavior.
The recognition of this technology within an international standard reflects a broader shift in the industry toward more sophisticated analytical tools capable of addressing the complexities of modern biotherapeutics. As gene therapy products become more advanced and diverse, traditional measurement approaches may no longer be sufficient to meet the demands of regulatory agencies and manufacturing requirements.
Addressing Industry-Wide Challenges
The inclusion of LumaCyte’s analytical approach in ISO 16921-2 also highlights ongoing efforts to address long-standing challenges in viral vector measurement. One of the most prominent issues has been the variability observed in adeno-associated virus (AAV) titer measurements, a critical factor in the development of many gene therapies.
Inconsistent titer results can have far-reaching implications, affecting everything from lot release decisions to cross-site comparability and overall supply chain reliability. For example, discrepancies between different analytical methods can lead to uncertainty بشأن product potency, potentially impacting both clinical outcomes and regulatory approvals.
As the industry moves toward larger-scale manufacturing and broader patient access, these challenges become even more pronounced. Ensuring that viral vector measurements are accurate, reproducible, and aligned across different settings is essential for maintaining product quality and patient safety.
By incorporating advanced analytical methods into a standardized framework, ISO 16921-2 aims to provide a foundation for more consistent and reliable measurements. This, in turn, supports improved process control, reduced variability, and greater confidence in decision-making לאורך the product lifecycle.
Real-World Application and Industry Collaboration
The practical impact of ISO-recognized analytical methods can already be seen in real-world applications. One notable example is the use of LumaCyte’s Radiance® platform by the ATCC in the characterization of its Human Adenovirus Type 5 Reference Material (ATCC VR-1516™).
Reference materials play a crucial role in ensuring consistency and comparability across different laboratories and studies. By providing a standardized benchmark, they enable researchers and manufacturers to validate their analytical methods and ensure alignment with industry standards.
In this case, advanced measurements generated באמצעות the Radiance® platform have supported precise quantification of infectious viral titers, enhancing the reliability of the reference material. The associated Certificate of Analysis (CoA), which is publicly available through ATCC, further reinforces transparency and alignment with the ISO standard.
This collaboration illustrates how standardized analytical approaches can be integrated into existing workflows to improve data quality and facilitate global harmonization. As more organizations adopt these methods, the benefits are expected to extend across the entire ecosystem of cell and gene therapy development.
Supporting Regulatory Alignment and Commercial Scale-Up
Another critical aspect of ISO 16921-2 is its role in supporting regulatory alignment. As gene therapies progress from clinical trials to commercial production, regulatory agencies require comprehensive and consistent data to evaluate product safety and efficacy.
Standardized quantification methods can help streamline this process by providing a common framework for data generation and reporting. This reduces ambiguity and facilitates communication between sponsors, manufacturers, and regulators, ultimately accelerating the path to market.
The standard is particularly relevant for AAV-based therapies, which have emerged as a leading platform in gene therapy. As these therapies move toward commercialization, ensuring consistent and reliable viral vector measurements is essential for scaling up production and maintaining product quality.
By addressing these needs, ISO 16921-2 supports not only regulatory compliance but also the broader goal of expanding patient access to life-changing therapies.
Broad Applicability Across Viral Vector Systems
While much of the focus has been on AAV, the ISO 16921-2 standard is designed to be broadly applicable across a wide range of viral vector systems. These include adenovirus, vesicular stomatitis virus (VSV), baculovirus, lentivirus, and other delivery platforms used in both therapeutic and vaccine development.
This versatility ensures that the standard can be applied across مختلف stages of research, development, and manufacturing, making it a valuable resource for organizations working with diverse viral systems. By providing a unified framework, the standard helps bridge gaps between different technologies and applications, fostering greater collaboration and innovation.
Leadership Perspective on Industry Impact
Renée Hart, President and Chief Business Officer of LumaCyte, emphasized the importance of precision in viral vector quantification, noting its direct impact on patient safety, product comparability, and supply chain stability. She highlighted the inclusion of optical and fluidic force measurements in the ISO standard as a reflection of the industry’s evolving needs.
According to Hart, advanced analytical technologies are essential for improving process control and reducing variability, particularly as gene therapies become more complex and widely adopted. The recognition of these methods within an international standard represents a significant validation of their value and potential.
A Step Forward for the Future of Gene Therapy
The publication of ISO 16921-2:2026 marks an important milestone in the maturation of the cell and gene therapy industry. By establishing clear guidelines for viral vector quantification, the standard provides a foundation for more consistent, reliable, and scalable manufacturing processes.
For companies like LumaCyte, the inclusion of their technology in this framework not only validates their approach but also positions them as key contributors to the future of biopharmaceutical analytics. As the industry continues to evolve, such innovations will play a critical role in overcoming technical challenges and enabling the next generation of therapies.
In summary, LumaCyte’s inclusion in the ISO 16921-2:2026 standard represents a significant advancement in the standardization of viral vector quantification. By recognizing the value of optical and fluidic force-based measurements, the standard reflects the industry’s commitment to adopting cutting-edge technologies that enhance precision, reproducibility, and scalability.
As gene therapies and vaccines continue to transform modern medicine, the importance of reliable analytical methods cannot be overstated. With the support of global standards like ISO 16921-2, the industry is better equipped to deliver safe, effective, and accessible treatments to patients worldwide.
About LumaCyte
LumaCyte is an advanced bioanalytical instrumentation company that delivers quantitative, descriptive, and predictive data insights into cellular systems used in advanced biologics and advanced therapy medicinal product manufacturing. Its platforms enable real time, label free measurement of critical cellular attributes, supporting deeper process understanding and driving consistency, quality, and confidence across therapy development and commercial manufacturing.
Source Link:https://www.businesswire.com/
